Subsequent analysis displayed that, despite both AAV‐GSN and anti‐PD‐1 monoclonal antibody being able to solely inhibit tumour growth, combining AAV‐GSN and PD‐1 blockade treatments could remarkably decrease tumour growth and tumour volume compared to therapy with AAV‐GSN or PD‐1 blockade alone (Figure 7B–D). Here, PDCD1 is linked to neoplasm.